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 ABSTRACT
Introduction: Kidney transplant improves survival even in highly -sensitized (HS) patients. To overcome their 
disadvantage in accessing transplantation, those with high Complement Dependent Cytotoxic PRA (CDC -PRA) 
receive additional points during allocation. Whether this strategy reaches all HS patients and how long they wait 
for a transplant is largely undetermined. Methods: Patients on our unit’s active wait -list for kidney transplanta-
tion in the year 2014 were analyzed. CDC -PRA and calculated PRA (cPRA) were recorded. To obtain cPRA, anti-
bodies in the last serum available specific for HLA -A,  -B or –DR with an intensity > 1000 MFI were considered. 
Results: The cPRA values in the population (N=551) were 0% (N=312), 1 ‑79% (N=118) and ≥ 80% (22%; N=121). 
Among these groups, the proportion of women (29.5, 55.9 and 61.2%, P<0.001), prior sensitizing events (43.3, 
80.5 and 96.7%, P<0.001) and time on dialysis (median of 3.9, 4.1 and 6.0 years, P<0.001) increased with cPRA, 
respectively. In most of those with a cPRA ≥ 80%, the CDC ‑PRA raised no suspicion of HS status (median 0%, 
P25 -75 0 -8%) and only 35 (28.9%) or 12 patients (9.9%) had a CDC -PRA in the peak serum higher than 50 or 80%, 
respectively (cut -offs needed to obtain additional points during allocation). HS patients by cPRA corresponded 
to 71% vs 15% of patients waiting for ≥ or <8 years, respectively (P<0.001). Even after exclusion of patients with 
a CDC -PRA above 50%, this disproportionate representation remained (58% versus 13%, P<0.001). Conclusion: 
HS patients as measured by cPRA remained longer on the wait -list, both in the primary analysis and when exclud-
ing those with a CDC -PRA> 50%. Moreover, only 30% of HS by cPRA patients received the extra points designed 
to improve their transplantability. We consider that both CDC -PRA and cPRA should be taken into account when 
defining HS status.
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 INTRODUCTION
In end stage renal disease, kidney transplantation is 
associated with increased survival and improved quality 
of life when compared to remaining on dialysis1.
Since kidneys available for transplantation are scarce, 
there has been much debate regarding the ideal alloca-
tion system. An optimal system should maximize the 
chance of success of each transplant while giving all the 
candidates the same odds of being eligible for transplan-
tation (balancing the principles of utility and justice)2. 
As established by Ordinance nº 6537/2007 (see Table I), 
the Portuguese allocation system takes into account time 
on dialysis and number of HLA compatibilities. Also, to 
compensate for the disadvantage that highly -sensitized 
(HS) patients have in accessing transplantation, those 
with Complement Dependent Cytotoxic PRA (CDC -PRA) 
≥ 50 or 80% (common thresholds used to define HS sta-
tus) are awarded extra points during kidney allocation. 
Moreover, in patients with CDC ‑PRA ≥ 80% it is not man-
datory that donor and receptor have identical AB0 blood 
types; only AB0 -compatibility is required. Although in 
the 2007 Ordinance the selection of patients with CDC-
‑PRA ≥ 80% was made at a national level, since the pub-
lication of Ordinance nº11420/2008, their selection is 
made only regionally, which lowered the pool of donors 
available for these patients. In sum, the Portuguese allo-
cation policy already aims to compensate for the disad-
vantage hypersensitized patients (HS) have in accessing 
transplantation, but so far only hypersensitized patients 
defined by CDC ‑PRA ≥ 50% have access to special alloca-
tion criteria.
In order to clarify the results presented in this study, 
it is imperative to perform a brief review of four essen-
tial concepts: CDC -PRA, calculated PRA, virtual cross-
-match and cytotoxic cross -match.
First, is must be remembered that CDC -PRA and cal-
culated PRA are performed prior to transplantation. They 
refer to the comparison of the anti -HLA antibodies present 
in the candidate for kidney transplantation with the HLA 
phenotype of the population. Therefore, they aim to 
reflect the percentage of donors in the population who 
would not be immunologically compatible with the recipi-
ent, and hence the transplantability of each recipient.
When obtaining the Complement Dependent Cyto-
toxic Panel Reactive Antibody (CDC -PRA) the serum of 
the candidate to kidney transplantation is put together 
with a panel of cells of different donors representative 
of the HLA phenotypes of the population. If the serum 
contains anti -HLA antibodies capable of engaging a 
complement -dependent cytotoxic (CDC) response, the 
cell with the correspondent HLA antigen becomes lysed. 
The CDC -PRA corresponds to the percentage of cells 
in the panel that become lysed and thus to the percent-
age of donors in the population against which the recipi-
ent would develop a CDC response. This CDC -PRA is 
the one used by the current allocation algorithm in 
identifying hypersensitized candidates.
In contrast, to obtain the calculated PRA (cPRA), the 
serum of the candidate is screened for the presence 
of anti -HLA antibodies, and antibodies specificities 
(identified by Luminex) are compared with the HLA 
phenotypes present in the population (estimated from 
the population of bone marrow donors1 or the popula-
tion of previous kidney donors). The percentage of 
donors in the population against which the candidate 
has anti -HLA antibodies is the cPRA3. The strength of 
each antibody present is also measured, in mean fluo-
rescent intensity (MFI) units, and only antibodies with 
a MFI ≥ 1000 are considered in cPRA. No clear cPRA 
threshold has been determined in order to consider a 
patient HS, but most studies use the value ≥80%.
Whereas CDC -PRA and cPRA are performed prior to 
transplantation and aim to determine the percentage 
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Table I
Portuguese Kidney Allocation Algorithm – adapted from Ordinance 
n.º 6537/2007
Criteria Points awarded
HLA Mismatches:
 No mismatches on A, B or DR (full house)
 No mismatches on B or DR
 One mismatch on either B or DR
 One mismatch on B and one on DR
 More than two mismatches on B and DR
12
8
4
2
1
Hypersensitized patients with:
 CDC ‑PRA≥ 80 %
 CDC ‑PRA≥ 50 %
8
4
Waiting time since dialysis was started:
 Each month 0.1
Age:
 < 11 years
11 to 18 years
5
4
Retransplantation:
  Each month since dialysis was restarted (or time since 
first dialysis session if graft was loss in the first three 
months after transplantation)
0.1
Age difference between donor and receptor:
 Donor > 60 years – Receptor < 55 years
 Donor < 40 years – Receptor > 55 years
 All other groups
0
0
4
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of donors in the population who would not be immu-
nologically compatible with the recipient, virtual and 
cytotoxic cross -matches are performed after a specific 
donor becomes available and aim to avoid attributing 
a kidney to an HLA -incompatible recipient.
Virtual cross -match is performed first and refers to 
the comparison, by the computer, of the HLA antibodies 
present in each candidate with the HLA antigens pre-
sent in the kidney available. All candidates with specific 
antibodies against the loci A–, B - or DR - of the donor’s 
HLA are immediately excluded. If the virtual cross-
-match is negative, the candidates pursue the cytotoxic 
cross -match, where the serum of each candidate is put 
together with lymphocytes of the donor. If the serum 
contains HLA donor specific antibodies capable of 
engaging a CDC response, the cells of the recipient 
become lysed and the candidate is excluded.
Although CDC -PRA and cPRA are performed prior to 
transplantation (considering the pool of HLA phenotypes 
of the population) and virtual and cytotoxic cross -matches 
are performed after a kidney donor is available (consider-
ing the specific HLA phenotype of the kidney to be donat-
ed), there is a relationship between them. In fact, cPRA 
reflects the probability of obtaining a positive virtual 
cross -match and CDC -PRA the probability of obtaining a 
positive CDC cross -match. Since to proceed in the selec-
tion process the candidate must first obtain a negative 
virtual cross -match, the cPRA is a major determinant of 
the transplantability of each candidate reflecting (more 
accurately than CDC -PRA) the candidate’s chance of 
receiving a kidney transplant2,4,5. The French and Ameri-
can entities responsible for organ allocation (Agence de 
la Biomedicine and OPTN/UNOS, respectively) therefore 
currently use cPRA as the measure of sensitization for 
awarding extra allocation points. This happened seven 
years ago, in 20096,7. In Portugal, the use of cPRA has 
already been proposed to become part of the kidney 
allocation algorithm2,5, but this has not yet happened.
Our aim was to determine candidate’s waiting time 
according to their cPRA and if the additional points 
offered to HS patients as defined by CDC -PRA by the 
current allocation system are also benefiting HS patients 
as defined by cPRA.
 SUBJECTS AND METHODS
Patients on the active list for kidney transplantation 
in Hospital de Santo António in 2014 were considered. 
Patients with no serum available were excluded. 
CDC -PRA and cPRA were obtained for each patient. For 
cPRA, the most recent serum available was used. 
Patient’s serum was screened to identify antibodies 
against various HLA class I and class II loci (HLA -A, HLA-
-B, HLA -C and HLA -DR, HLA -DQ, HLA -DP). If the screen-
ing test was positive, the antibodies were identified 
using Single Antigen Beads Luminex technology. The 
periodic screening for antibodies against HLA is part of 
the protocol defined for maintenance of candidates on 
the active waiting list for kidney transplantation (speci-
fied in Regulatory Circular 01/DQS, of 7th January 2009, 
issued by the Directorate General of Health). In accord-
ance with these rules, when determining cPRA only 
the anti -HLA antibodies against – A, – B and – DR were 
considered. An antibody against HLA was considered 
positive if it had a mean fluorescence intensity (MFI) 
equal or superior to 1000. The frequency of HLA phe-
notypes of the population of the Northern part of Por-
tugal was estimated from the frequency of bone mar-
row donors’ HLA phenotype, available in the database 
of the Centro do Sangue e Transplantaçãodo Porto. 
Waiting time corresponds to time since dialysis was 
started, and was therefore calculated by subtracting 
the date of the first dialysis session from the date of 
sera collection.
 STATISTICAL ANALYSIS
Continuous data were described using mean (stand-
ard deviation) or median (interquartile range) and 
categorical data were expressed as numbers (frequen-
cies). Categorical data were compared using Pearson 
χ2 test (χ2 for trend test was used when in the presence 
of a variable with 3 ordinal categories) or Fisher’s exact 
test, as appropriate. Continuous variables were com-
pared with Student t -test (or one -way ANOVA for vari-
ables with 3 categories) or Mann -Whitney U test 
(Kruskal -Wallis test for variables with 3 categories), as 
appropriate. A Cohen’s Kappa analysis was performed 
to assess inter -rater reliability between CDC -PRA and 
cPRA.
A two -sided P value <0.05 was considered as statistically 
significant. Statistical calculations were performed using 
SPSS for Mac, version 23.0 (SPSS Inc., Chicago, IL, USA).
 RESULTS
We included 551 patients and divided them into 
three groups (those with cPRA of 0%, those with cPRA 
between 1 and 79% and those with cPRA equal or 
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superior to 80%). Female gender prevalence was higher 
in the cPRA>0% groups. Of the 551 patients included, 
22% (N=121) had a cPRA ≥ 80%. HS patients included 
more women and more patients with previous sensitiz-
ing events (previous transplant, pregnancy or blood 
transfusion). Half of these patients –50.4% (n=61) – had 
been on the waiting list for more than 5 years; 31.4% 
(n=38) for more than 8 years and 18.2% (n=22) for 
more than 10 years. The median time on dialysis wait-
ing for a transplant increased significantly with the 
cPRA (3.9 years in those with a cPRA of 0%; 4.1 years 
in those with a cPRA between 1 and 79% and 6.0 years 
in those with a cPRA equal or superior to 80%, P<0.001) 
(Fig. 1). Additional data regarding demographics, per-
centage of patients with prior sensitizing events, time 
on dialysis and values of CDC -PRA and cPRA for HLA 
class I or II antigens are presented in Table II (both 
medians and percentiles are provided). The intensity 
of the antibodies found (in MFI units) and their char-
acterization according to specific HLA antigen is 
described in Table III.
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Table II
Demographics and characteristics of HLA -specific antibodies present in patients waiting for a kidney transplant at the transplantation unit of Hospital 
de Santo António, in Porto
N=551 cPRA=0%(n=312)
0<cPRA<80%
(n=118)
cPRA≥80%
(n=121) Global p ‑value
p ‑value
(0<cPRA<80% vs cPRA≥80%)
Age 50.5±12.2 51.4±9.9 48.4±11.9 0.112 0.118
Female(%) 29.5% 55.9% 61.2% <0.001 0.433
Previous kidney transplant 4.8% 25.4% 68.6% <0.001 <0.001
Previous blood transfusion 32.4% 52.5% 66.9% <0.001 0.023
Previous pregnancy 17.6% 45.8% 44.6% <0.001 0.897
>0 sensitizing events 43.3% 80.5% 96.7% <0.001 <0.001
Years on dialysis
Median
P25 -75
P10 -90
3.9
2.6 -5.1
1.7 -6.7
4.1
3.0 -6.0
2.3 -7.4
6.0
4.3 -9.7
2.7 -14.3
<0.001 <0.001
Maximum CDC -PRA (%)
Median
P25 -75
P10 -90
0
0 -0
0 -2
0
0 -2
0 -10
23
2 -54
0 -83
<0.001 <0.001
Latest CDC -PRA (%)
Median
P25 -75
P10 -90
0
0 -0
0 -0
0
0 -0
0 -0
0
0 -8
0 -35
<0.001 <0.001
CDC -PRA>50% (n=40) 0 5 (4.2%) 35 (28.9%) <0.001 <0.001
CDC -PRA>80% (n=12) 0 0 12 (9.9%) <0.001 <0.001
cPRA against class I
HLA -specific antigens (%)
Median
P25 -75
P10 -90
0 26.86
2.10 -53.24
0 -70.39
96.69
84.27 -99.55
33.42 -99.96 
<0.001 <0.001
cPRA against class II
HLA -specific antigens (%)
Median
P25 -75
P10 -90
0 4.21
0 -37.50
0 -65.66
72.72
12.0 -92.57
0 -97.72
<0.001 <0.001
Maximum cPRA (%)
Median
P25 -75
P10 -90
0 38.30
22.05 -63.33
9.98 -72.72
97.46
92.90 -99.60
84.87 -99.96
<0.001 <0.001
Figure 1
Time since dialysis was started in candidates for kidney transplanta-
tion, according to cPRA.
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Since time waiting for a kidney transplant varies accord-
ing to the candidate’s blood group, this was considered 
in a separate analysis (Table IV). The most frequent blood 
group of candidates for kidney transplant in our unit was 
group 0, followed by group A, B and AB. When comparing 
time on dialysis according to cPRA among patients 
grouped by blood type, waiting time continued to increase 
significantly with cPRA in all AB0 isogroups (Fig. 2).
Implications for patients waiting for a kidney transplant of using the calculated panel reactive antibody (cPRA)
Table III
Characterization of the antibodies found according to specific HLA -antigens
N=551 cPRA=0%(n=312)
0<cPRA<80%
(n=118)
cPRA≥80%
(n=121)
p ‑value
(0<cPRA<80%
vs
cPRA≥80%)
Antibodies against HLA -A (%)
Median (MFI)
 – 34.5
2125
44.6
8143
0.110
<0.001
Antibodies against HLA - B (%)
Median (MFI)
 – 35.3
2901
46.3
8954
0.087
<0.001
Antibodies against HLA - C (%)
Median (MFI)
 – 12.9
2238
37.2
4565
<0.001
0.059
Antibodies against HLA - DR (%)
Median (MFI)
 – 30.2
3769
33.9
8220
0.541
<0.001
Antibodies against HLA - DQ (%)
Median (MFI)
 – 16.4
4599
28.1
7649
0.030
0.043
Antibodies against HLA - DP (%)
Median (MFI)
 – 18.1
2488
20.7
3884
0.619
0.501
MFI sum (sum of the MFI values of the antibodies identified)
Median
P25 ‑75
P10 ‑90
 –
3673
0 ‑9309
0 ‑15204
11387
0 ‑26117
0 ‑44481
0.025
Figure 2
Time since dialysis was started in candidates for kidney transplantation, according to cPRA, after grouping patients by blood type.
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The majority of the HS patients are relatively young. 
In fact, 82.6% (n=100) were aged less than 60 years old 
and 51.2% (n=62) aged less than 50 years old. Four HS 
candidates were children.
HS patients by cPRA corresponded to 71% vs 15% 
of patients waiting for more or less than 8 years, 
respectively (P<0.001) (Fig. 3). Even after exclusion of 
pat ients with a CDC -PRA above 50%, this 
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Figure 3
Comparison of cPRA between two groups of patients: those waiting 
for less than and those waiting for longer than eight years for  
a transplant.
 
Figure 4
Comparison of cPRA between two groups of patients:  
Group 1) Patients waiting for a kidney transplant for < 8 years; 
Group 2: Patients waiting for a kidney transplant for > 8 years.
 
Table IV
Time on dialysis waiting for a kidney transplant according to cPRA, in patients with different blood types
N=551
cPRA=0%
(n=312)
0<cPRA<80%
(n=118)
cPRA≥80%
(n=121)
Global
p ‑value
p ‑value
(0<cPRA<80% vs 
cPRA≥80%)
AB0 group
 A
 B
 AB
 0
122 (39.1%)
11 (3.5%)
6 (1.9%)
173 (55.4%)
53 (44.9%)
8 (6.8%)
2 (1.7%)
55 (46.6%)
64 (52.9%)
7 (5.8%)
6 (5.0%)
44 (36.4%)
0.012 0.232
Years on dialysis – A
Median
P25 -75
P10 -90
3.5
2.2 -4.4
1.0 -5.0
3.6
2.7 -4.5
2.2 -5.5
5.5
4.1 -9.8
2.6 -14.9
<0.001 <0.001
Years on dialysis –B+AB
Median
P25 -75
P10 -90
2.5
2.2 -3.0
1.7 -5.4
3.0
2.4 -4.0
1.1 -8.6
8.1
4.3 -13.9
2.3 -21.5
0.001 0.007
Years on dialysis – 0
Median
P25 -75
P10 -90
4.6
3.0 -6.1
1.9 -7.1
5.9
4.6 -6.9
3.0 -7.8
6.1
4.3 -9.1
2.9 -10.9
<0.001 0.144
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disproportionate representation remained (58% versus 
13%, P<0.001) (Fig. 4).
In the group with a cPRA ≥ 80%, the median of the 
CDC -PRA raised no suspicion of HS status (median CDC-
-PRA of 0%, P25 -75 0 -8% – Table II). In fact, only 35/121 
patients (28.9%) and 12/121 (9.9%) had a CDC -PRA in 
the peak serum higher than 50 or 80%, respectively (50 
and 80% correspond to the cut -offs established by Por-
tuguese law to receive 4 or 8 additional points in the 
kidney allocation algorithm – Ordinance nº 6537/2007 
from April 3rd).
Cohen’s Kappa analysis showed low agreement 
between CDC -PRA and cPRA when defining HS state 
(Table V). In fact, 71% of hypersensitized patients 
defined by cPRA> 80% have a CDC -PRA < 50%, receiving 
no compensatory points during the allocation 
process.
 DISCUSSION
Twenty -two percent of the patients analyzed were 
found to have a cPRA equal or superior to 80%. This 
percentage is significant and is twice as high as that 
found in the United States in 2010 (11%)6. The reality 
of the French transplantation unit of Saint -Louis seems 
more similar to ours, with 16.7 % of patients on the 
waiting list for kidney transplant in 2010 having a cPRA 
higher than 85%7.
Previous kidney transplant was shown to be a major 
sensitizing event, as has already been reported. C. 
Lechaufer et al., for example, found that of the 93 
patients on the waiting list aiming for retransplantation, 
82.8% were considered to be sensitized due to the pres-
ence of HLA specific antibodies7.
Our data demonstrate that HS patients as defined 
by cPRA wait longer for a kidney transplant. Bruno A. 
Lima et al.1 reported a median waiting time among all 
candidates for deceased -donor kidney transplantation 
in the same transplant unit that we analyzed of 59.5 
months (4.96 years). This paper considered patients 
transplanted between 2008 and 2011 (after the 2007 
ordinance was issued, which established the current 
allocation policy). These findings are consistent with 
the ones now reported. The median waiting time of 
patients with cPRA ≥ 80% (6.0 years) was superior to 
the median previously reported, consolidating the 
hypothesis that these HS patients face an unfair disad-
vantage in accessing transplantation. Also, these results 
show that the current allocation system is not com-
pensating for this disadvantage in an efficient manner. 
Because these patients are held back in the selection 
process, they are then expected to be kept waiting for 
a transplant. This problem is therefore expected to 
aggravate, as HS candidates accumulate on the waiting 
list, further increasing the waiting time difference 
between those with low and high cPRA.
The chance that each candidate has of being trans-
planted must be stated clearly, if we aim for a transpar-
ent kidney allocation system2. Identifying patients with 
high cPRA may help the physician to inform patients 
about their real chance of being transplanted in the 
current allocation system (in France, for example, the 
theoretical number of compatible donors can be esti-
mated to decide whether the sensitized patient has a 
donor flow considered to be sufficient or if undergoing 
a desensitization strategy would be more advanta-
geous7). That information can also be useful for patients 
in doubt as to whether to proceed with a living donation 
process. In the face of the transplantability of each 
individual patient, alternatives such as paired donor 
transplantation5 can also be discussed. These aspects 
gain importance if we consider that, according to our 
data, HS patients are relatively young (48 years on aver-
age). Finally, time on dialysis while waiting for a kidney 
transplant is a crucial determinant of the success of 
the transplant itself1; hence the importance of making 
sure that patients’ access to transplantation is equal 
among all the candidates, and that the success of trans-
plantation of HS patients is not jeopardized by an 
unfairly prolonged waiting time.
When analyzing waiting time in patients with differ-
ent blood groups, our results were also consistent with 
those previously reported. Between 2008 and 2011 in 
Porto1, blood type A and 0 were the more frequently 
present, and AB the rarest. In that data series, blood 
type 0 candidates also waited longer than patients with 
other blood types for a kidney transplant. Although 
there was a change in the allocation policy in 2007 so 
that the recipient needs to be AB0 -identical to the 
donor (AB0 compatibility is not sufficient to proceed 
with transplantation), the heterogeneous waiting time 
according to blood type still persists.
In the analyzed cohort, patients had higher cPRA than 
CDC -PRA. This was expected, as HLA -specific antibodies 
that connect to the beads containing a specific HLA anti-
gen may be present in amounts insufficient to engage 
a complement -dependent cytotoxic response leading to 
cell lysis. Moreover, these results are consistent with 
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those reported in the literature6. Also, in Portugal the 
CDC -PRA identifies only cytotoxic antibodies against HLA-
-A and HLA -B (the assay employed does not identify 
antibodies specific for HLA -DR, which are included when 
performing the virtual cross -match). This may help 
explain why patients have higher cPRA (that also takes 
into consideration antibodies against HLA -DR) than CDC-
-PRA. However, the opposite is also possible, with previ-
ous studies reporting cases of patients with CDC -PRA 
higher than the cPRA3. The main reason for this is the 
presence of IgM antibodies in the candidate. In other 
countries, the discrepancy between CDC and calculated 
PRA may be also due to the presence of DP or DQ HLA 
antibodies not identified by the cytotoxic assay. Since in 
Portugal only antibodies against HLA -A, HLA -B and HLA-
-DR are considered in the virtual cross -match, only these 
were considered in our study to calculate the cPRA.
Despite all the additional information provided by 
the cPRA, the authors consider that the cPRA should 
be viewed as a complement (not as a replacement) of 
the CDC -PRA, and the virtual cross -match should be 
considered as the first step evaluation, with a cytotoxic 
cross -match performed routinely thereafter5.
Patients with high CDC -PRA are less likely to find a com-
patible kidney. As such, previous studies have already 
demonstrated that they wait longer for a transplant. Since 
a considerable amount of those with high CDC -PRA also 
have high cPRA, it could be argued that CDC -PRA could be 
responsible for the increased waiting time among the HS 
defined by the cPRA. However, our results show that, even 
after excluding patients with CDC ‑PRA> 50%, cPRA ≥ 80% 
continues to be associated with an increased waiting time. 
Therefore, patients with cPRA ≥ 80% and a CDC ‑PRA< 50% 
also wait longer but do not receive compensatory points 
in the allocation algorithm. This issue affects a significant 
amount of HS patients, since the majority (70%) of patients 
with cPRA ≥ 80% do not receive additional points during 
allocation (see Cohen Kappa analysis in Table V showing 
low agreement between CDC -PRA and cPRA).
Of the 475 transplants performed in Porto between 
2008 and 2011, only 1.5% of the recipients had a peak 
CDC ‑PRA ≥ 50%1. Conversely, in the United States between 
2001 and 2002, 7.3% of the total of kidney transplants 
were performed in HS (CDC ‑PRA ≥ 80%) patients4.
Other allocation systems struggle with the difficulty in 
providing HS patients equal access to kidney transplanta-
tion. In the United States, for example, although the virtual 
cross -match is performed early in the recipient’s selection 
process, it is the transplant centre’s responsibility to decide 
the threshold of intensity of anti -HLA antibodies (meas-
ured in MFI) above which the virtual cross -match is con-
sidered positive and the candidate is excluded6. This cut-
-off must not be set too low (in HS candidates many HLA 
antigens would be considered unacceptable, preventing 
them from proceeding to the cytotoxic cross -match that 
might turn out to be negative) nor too high (so that the 
efficiency of allocation is not compromised by the need 
to perform an exceedingly large number of CDC cross-
-matches that will most definitely turn out to be positive6). 
Instead, the transplant centre needs to balance individu-
ally the risk and benefit of each candidate receiving an 
allocated kidney, taking into account the possibility of 
undertaking a desensitization therapy, as well as the prob-
ability of getting an alternative donor against which the 
recipient could have an improved HLA -compatibility.
However, the current Portuguese system does not allow 
each transplant unit to consider different MFI thresholds 
to define unacceptable antigens adapted to the candi-
date’s immunological complexity when performing the 
virtual cross -match (any antibody with intensity higher 
than 1000 MFI, either in the last or in any of the historical 
sera, is considered unacceptable). Therefore, the majority 
of these HS patients are immediately excluded in the vir-
tual cross -match, so that many of them will never receive 
additional points. Proof that the compensation points are 
ineffective is the fact that despite the current legislation, 
HS patients continue to wait significantly longer for a kid-
ney transplant. In other words, these patients’ long waiting 
times places them high on the candidates’ list only to 
immediately exclude them in the virtual cross -match. It 
could be feared that a legislation change could reverse 
the situation by providing HS patients with preferential 
access to transplantation, creating a new injustice. Since 
the allocation policy in the United States started to con-
sider cPRA to define HS status, the percentage of 
Rita Magriço, Jorge Malheiro, Sandra Tafulo, Sofia Pedroso, Manuela Almeida,  
La Salete Martins, Leonídio Dias, António Castro -Henriques, António Cabrita
Table V
Cohen’s Kappa analysis, comparing agreement between CDC -PRA and cPRA when defining hypersensitized status
cPRA<80% (n=430) cPRA≥80% (n=121) Kappa
CDC -PRA <50% (n=511) 425 (98.8%) 86 (71.1%) 0.366
CDC ‑PRA ≥50% (n=40) 5 (1.2%) 35 (28.9%)
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transplants performed in HS patients increased to 15.8% 
in 2009 -2010. HS and nonsensitized patient’s transplant 
rates became closer without giving any unfair advantage 
in transplantation access to any of these two groups6.
As established by Ordinance nº 6537/2007, Ordinance 
nº 11420/2008 and further specified in the Regulatory 
Circular Nº 15/GDG of 7 September 2009, transplantation 
should only be considered in the absence of known previ-
ous allosensitization against specific antigens present in 
the donor. A positive virtual cross -match reflects the pres-
ence of allosensitization against the donor. Therefore, 
these candidates are immediately excluded, even though 
they might not have a positive cytotoxic cross -match. 
Moreover, if the candidate has had a positive donor spe-
cific antibody in any of the previously collected sera, he/
she cannot proceed with transplantation. Although previ-
ous sera results should be considered in evaluating immu-
nological risk and when planning desensitization strate-
gies, we consider that only the antibodies against the 
donor present in the most recent serum should be taken 
into account in the decision on whether the candidate 
should proceed to a cytotoxic cross -match.
Also, since Ordinance nº 11420/2008 was published, 
the kidney selection for hypersensitized patients is no 
longer performed at a national level, but only at a 
regional level. By lowering the available pool of donors 
for these patients, the chance HS patients have of find-
ing a compatible kidney has been further reduced.
In conclusion, several aspects could be improved in 
order to compensate for the disadvantage HS patients 
have in accessing transplantation (Table VI). The authors 
consider that the identification of patients with high cPRA 
is important and that cPRA should be shared routinely 
with the transplantation centre. Also, the allocation sys-
tem could be improved if cPRA was taken into considera-
tion (by setting an individualized MFI cut -off on the virtual 
cross -match in the face of the antibody type and its 
relationship to the cytotoxic assays and by giving addi-
tional compensatory points to all patients with high PRA 
– either cPRA or CDC -PRA). Moreover, the authors con-
sider that these patients benefit from an individualized 
evaluation by a specific member of the transplantation 
unit, including design of appropriate desensitization strat-
egies in the face of the donor flow for the HLA phenotype 
of the candidate, inclusion in the paired kidney donation 
programme, or a combination of both. Finally, selecting 
donors for HS patients at a national (not regional) level 
and attributing HS patients undergoing desensitization 
a higher degree of urgency in the allocation algorithm 
should be considered (as long as the waiting time of the 
candidate exceeds the average waiting time of the 
remainder candidates). All these proposals should be 
discussed nationally, in order to obtain consensus 
between the different transplantation units.
Disclosure of Conflicts of Interest: None declared.
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Implications for patients waiting for a kidney transplant of using the calculated panel reactive antibody (cPRA)
Table VI
Proposed changes to the kidney allocation policy in order to compensate for the disadvantage HS patients have in accessing kidney transplantation
cPRA provided routinely to the transplantation centre
MFI cut -off for each HLA antigen specified by the transplantation unit, according to immunological study of the candidate and desensitization strategies being provided
Awarding additional compensatory points during allocation to hypersensitized patients defined by cPRA ≥80% (and not only to patients with CDC ‑PRA ≥ 50%)
Evaluate individually HS patients by a specific member of the transplantation unit (define whether desensitization is feasible, propose introduction in living or 
paired donation kidney programs)
Select donors to HS patients at a national level
Consider giving HS patients a higher degree of urgency in the allocation algorithm (as long as the waiting time of the candidate exceeds the average waiting time 
of the remainder candidates)
Discuss the proposed changes at a national level and monitor their impact
